Ramsay Health Care Board Members

Michael Siddle
Chairman
Appointed 27/05/14 (Appointed as a Director 26/5/75)

---

Mr Michael Siddle was appointed as Chairman of the Company on 27 May 2014, having formerly been Deputy Chairman for 17 years and a founding Director. He has built up significant knowledge of the business and the private hospital industry after starting with the Company in 1968. Mr Siddle has extensive experience in the management of private hospitals and has been integrally involved in Ramsay Health Care’s successful expansion through construction, mergers and acquisitions.

Mr Siddle is also a Trustee of the Paul Ramsay Foundation.

Committee memberships:

• People & Remuneration Committee (Member)
• Nomination & Governance Committee (Member)

Independence status:

• Non-independent

Peter Evans FCA
Deputy Chairman
Appointed 27/05/14 (Appointed as a Director 29/12/90)

---

Mr Peter Evans was appointed as Deputy Chairman of the Company on 27 May 2014, having formerly served as a Non-Executive Director since his appointment to the Board in 1990. Mr Evans began working with Ramsay Health Care in 1969. He is a Chartered Accountant who was in public practice for over 20 years with predecessor firms of KPMG. Mr Evans has specialised in the financial management of hospitals and has had extensive experience in the health care field for 50 years.

Mr Evans is also a Trustee of the Paul Ramsay Foundation and has been actively involved with several other charitable organisations over many years.

Committee memberships:

• Risk Management Committee (Chair)
• Audit Committee (Member)

Independence status:

• Non-independent

Craig McNally
CEO & Managing Director
Appointed 03/07/17

---

Mr Craig McNally was appointed Managing Director and Chief Executive Officer of Ramsay Health Care (Ramsay) on 3 July 2017, after serving seven years with Ramsay Health Care as Chief Operating Officer and 22 years prior to this in various roles including Head of Global Strategy and European Operations.

Mr McNally is one of Ramsay’s longest serving Executives having commenced with the Company in 1988. He was initially employed as a Hospital Executive in Ramsay’s Sydney-based mental health facilities, before taking over divisional responsibility for acute medical and surgical hospitals in the early nineties.

In 1995, he became Ramsay’s Head of Strategic Development, and for the last two decades has been responsible for the development and implementation of Ramsay’s growth strategy including brownfield expansions, international market assessments, mergers and acquisitions and new business strategies. As the Company’s chief negotiator and deal-maker he has been at the forefront of all the major acquisitions and deals completed by Ramsay Health Care. His unique ability to assess the opportunities and risks associated with new business ventures and to evaluate their ‘strategic fit’, as well as his sound judgement and insight, has ensured the Company’s successful growth both domestically and internationally.

In his role as head of Ramsay’s UK and European business, Mr McNally has been responsible for leading these teams through the challenging acquisition and merger phases and ensuring their successful integration with Ramsay Health Care and adoption of The Ramsay Way culture. His quiet but assured leadership style is well-respected throughout the organisation.

Prior to joining Ramsay Health Care in 1988, Mr McNally was an executive of a private hospital in Sydney following completion of a health administration degree at the University of New South Wales.

He is married with three children and an enthusiastic fan of football, baseball and rugby.

Alison Deans BA MBA GAICD
Non-Executive Director
Appointed 15/11/18

---

Alison Deans has 25 years’ experience building technology-enabled businesses involved in media, ecommerce, financial services and health, and across leadership roles as an executive, a director and in venture capital.

Ms Deans joined the Board of Ramsay Health Care in November 2018. She is also a Non-Executive Director of Cochlear Limited, SCEGGS Darlinghurst and Deputy Pty Ltd. She is also on the Investment Committee of MainSequence Ventures.

In her executive career Ms Deans was previously the CEO of eBay Australia and New Zealand, CEO of eCorp Limited, (a publicly listed portfolio of digital businesses), CEO of Hoyts Cinemas, and most recently CEO of netus Pty Ltd - a technology investment company acquired by Fairfax.

Ms Deans also spent seven years as a Consultant with McKinsey & Company and is currently a Senior Advisor with the firm. She holds a Master of Business Administration from the Stanford Graduate School of Business and a Master of Arts from Trinity College at Cambridge University.

In the past three years, Ms Deans has served as a Director of the following listed companies:

• Cochlear Limited (Appointed February 2015)
• Westpac Banking Corporation (Resigned December 2020)
• Insurance Australia Group Limited (Resigned October 2017)

Committee memberships:

• People & Remuneration Committee (Chair)
• Nomination and Governance Committee (Member)

Independence status:

• Independent

James McMurdo BSc (Economics), ACA
Non-Executive Director
Appointed 10/09/19

---

Mr James McMurdo has over 30 years finance and banking experience. He has a background in corporate advisory spanning across mergers and acquisitions, strategic advisory and financing with experience across multiple industries including the healthcare sector. He has held senior operating management roles and worked extensively in both the Asia Pacific and European regions.

Until July 2020, Mr McMurdo was Vice Chairman of Investment Banking for Deutsche Bank based in Hong Kong. He has held senior management roles at Deutsche Bank including Global Co-Head of Corporate Finance, Head of Corporate and Investment Bank for Asia Pacific and CEO for Australia and New Zealand. He sat on the firm’s Global Executive Committee for the Corporate and Investment Bank for four years.

Prior to this, Mr McMurdo was a Partner at Goldman Sachs where he held senior positions in the Investment Banking Division in Australia and Europe.

Mr McMurdo holds a degree in Economics from the University of Newcastle upon Tyne and is a member of the Institute of Chartered Accountants for England & Wales.

Committee memberships:

• Audit Committee (Member)

Independence status:

• Independent

Karen Penrose B.Com (UNSW) CPA FAICD
Non-Executive Director
Appointed 1/3/20

---

Ms Karen Penrose has had an extensive executive career in leadership and CFO roles, mainly in financial services. She is well-versed in financial management, customer outcomes and operating in a rapidly changing regulatory environment which stems from 20 years in banking with Commonwealth Bank and HSBC and eight years as a listed-company CFO.

Ms Penrose has been a full-time director since 2014 and is an experienced committee chair of audit and risk. In addition to being a Non-Executive Director of Ramsay Health Care, Ms Penrose also serves as a Director of Vicinity Centres, Bank of Queensland, and Estia Health. Ms Penrose is a member of Chief Executive Women and on the Board of Marshall Investments Pty Limited.

In the past three years, Ms Penrose has served as a Director of the following listed companies:

• Vicinity Centres (Appointed June 2015)
• Bank of Queensland (Appointed November 2015)
• Estia Health (Appointed October 2018)
• Spark Infrastructure Group (Resigned May 2020)
• Future Generation Global Investment Company Limited (Resigned October 2018)
• AWE Limited (Resigned April 2018)

Committee memberships:

• Audit Committee (Chair)
• Risk Management Committee (Member)

Independence status:

• Independent

Claudia Süssmuth Dyckerhoff PhD
Non-Executive Director
Appointed 30/10/18

---

Dr Claudia Süssmuth Dyckerhoff PhD joined the Ramsay Health Care Board in October 2018, bringing expertise in market growth strategies, business development, and operational performance improvement in hospitals.

Dr Süssmuth Dyckerhoff has extensive global experience in hospitals and health care across Europe, Asia, and the USA. She joined McKinsey & Company in Switzerland in 1995 and was transferred to the USA focusing on supporting health care companies, including pharmaceutical/medical device companies, payor, provider and health systems in Europe and the USA. In 2006, Dr Süssmuth Dyckerhoff transferred to China, was elected Senior Partner in 2010 and supported health care companies as well as governments across Asia. She also led McKinsey’s Asia-wide Health Systems and Services Sector.

Dr Süssmuth Dyckerhoff also supports three start-ups, and in September 2017 she joined the Board of med tech start-up Cyrcadia.

Dr Süssmuth Dyckerhoff studied Business Administration at the University of St Gallen, Switzerland as well as at ESADE, Barcelona where she graduated with an MBA/CEMS Master. She also holds a PhD in Business Administration from the University of St Gallen/University of Michigan Ann Arbor.

In the past three years, Dr Süssmuth Dyckerhoff has served as a Director of the following listed companies:

• Hoffmann La Roche (Appointed March 2016)
• Clariant AG (Appointed April 2016)

Committee memberships:

• Risk Management Committee (Member)

Independence status:

• Independent

David Thodey AO
Non-Executive Director (Appointed 28/11/17) and
Lead Independent Director (Appointed 1/03/20)

---

Mr David Thodey AO is a business leader who has had a strong executive career in the technology and telecommunications industries, with more than 30 years of experience creating brand and shareholder value.

In addition to being a Non-Executive Director and Lead Independent Director of Ramsay Health Care, Mr Thodey is currently Chairman of Australia’s national scientific research agency, the Commonwealth Scientific and Industrial Research Organisation (CSIRO), Chairman of Tyro Payments Limited (a leading alternative payments provider) and Xero Limited (a small business accounting software company).

Mr Thodey also had a successful career as CEO of Telstra, Australia’s leading telecommunications and information services company, and prior to that he was CEO of IBM.

Mr Thodey holds a Bachelor of Arts in Anthropology and English from Victoria University, Wellington, New Zealand, attended the Kellogg School of Management postgraduate General Management Program at Northwestern University in Chicago, USA, and was awarded an Honorary Doctorate in Science and Technology from Deakin University in 2016 and an Honorary Doctorate of Business from University of Technology Sydney in 2018.

Mr Thodey is also a Fellow of the Australian Academy of Technological Sciences and Engineering (ATSE) and the Australian Institute of Company Directors (AICD).

Mr Thodey was awarded an Order of Australia in 2017 for his service to business and the promotion of ethical leadership and workplace diversity.

In the past three years, Mr Thodey has served as a Director of the following listed companies:

• Xero Limited (Appointed June 2019)
• Tyro Payments Limited (Appointed November 2018)
• Vodafone Group Plc (Resigned July 2020)

Committee memberships:

• Nomination and Governance Committee (Chair)
• People & Remuneration Committee (Member)

Independence Status:

• Independent

Henrietta Rowe B Econ (Soc Sci) (Hons), LLB (Hons), FGIA
Group General Counsel & Company Secretary
Appointed 25/06/19

---

Henrietta was appointed Group General Counsel & Company Secretary on 25 June 2019 and is responsible for the Group legal and secretariat functions.

Henrietta has more than 13 years’ experience with leading global law firm, Herbert Smith Freehills, and in-house at the Commonwealth Bank of Australia, specialising in corporate governance, mergers and acquisitions, capital management, executive remuneration, as well as general corporate and contractual advice.

Henrietta holds a Bachelor of Economics (Social Sciences) (Honours) and a Bachelor of Laws (Honours) from the University of Sydney and is a Fellow of the Governance Institute of Australia.